Financing

CEL-SCI Announces $15 Million Financing

Published in Lab Business Week, May 6th, 2007

CEL-SCI Corporation (AMEX:CVM), a developer of immune-system based treatments for cancer and infectious diseases, announces that it has raised $15 million in new equity financing. The shares were sold at $0.75, a small premium over the closing price of the last two weeks.

The financing is accompanied by 10 million warrants at $0.75 and 10 million warrants at $2.00. The Company has agreed to register the shares involved in this financing.

Geert Kersten, Chief Executive Officer of CEL-SCI said, "These funds will allow us to move forward as planned to start our Phase III clinical trial in first line advanced primary head and neck cancer. This also...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Business Week

Source: Lab Business Week (2007-05-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry